tetano
Editor, Senior Moderator
Am J Public Health
. 2022 Jan;112(1):38-42.
doi: 10.2105/AJPH.2021.306568.
Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona
Megan Jehn[SUP] 1 [/SUP], Urvashi Pandit[SUP] 1 [/SUP], Susanna Sabin[SUP] 1 [/SUP], Camila Tompkins[SUP] 1 [/SUP], Jessica White[SUP] 1 [/SUP], Erin Kaleta[SUP] 1 [/SUP], Ariella P Dale[SUP] 1 [/SUP], Heather M Ross[SUP] 1 [/SUP], J Mac McCullough[SUP] 1 [/SUP], Susan Pepin[SUP] 1 [/SUP], Katherine Kenny[SUP] 1 [/SUP], Heidi Sanborn[SUP] 1 [/SUP], Natalie Heywood[SUP] 1 [/SUP], Amy H Schnall[SUP] 1 [/SUP], Timothy Lant[SUP] 1 [/SUP], Rebecca Sunenshine[SUP] 1 [/SUP]
Affiliations
Abstract
We conducted a community seroprevalence survey in Arizona, from September 12 to October 1, 2020, to determine the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the seroprevalence estimate to predict SARS-CoV-2 infections in the jurisdiction by applying the adjusted seroprevalence to the county's population. The estimated community seroprevalence of SARS-CoV-2 infections was 4.3 times greater (95% confidence interval = 2.2, 7.5) than the number of reported cases. Field surveys with representative sampling provide data that may help fill in gaps in traditional public health reporting. (Am J Public Health. 2022;112(1):38-42. https://doi.org/10.2105/AJPH.2021.306568).
. 2022 Jan;112(1):38-42.
doi: 10.2105/AJPH.2021.306568.
Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona
Megan Jehn[SUP] 1 [/SUP], Urvashi Pandit[SUP] 1 [/SUP], Susanna Sabin[SUP] 1 [/SUP], Camila Tompkins[SUP] 1 [/SUP], Jessica White[SUP] 1 [/SUP], Erin Kaleta[SUP] 1 [/SUP], Ariella P Dale[SUP] 1 [/SUP], Heather M Ross[SUP] 1 [/SUP], J Mac McCullough[SUP] 1 [/SUP], Susan Pepin[SUP] 1 [/SUP], Katherine Kenny[SUP] 1 [/SUP], Heidi Sanborn[SUP] 1 [/SUP], Natalie Heywood[SUP] 1 [/SUP], Amy H Schnall[SUP] 1 [/SUP], Timothy Lant[SUP] 1 [/SUP], Rebecca Sunenshine[SUP] 1 [/SUP]
Affiliations
- PMID: 34936397
- DOI: 10.2105/AJPH.2021.306568
Abstract
We conducted a community seroprevalence survey in Arizona, from September 12 to October 1, 2020, to determine the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the seroprevalence estimate to predict SARS-CoV-2 infections in the jurisdiction by applying the adjusted seroprevalence to the county's population. The estimated community seroprevalence of SARS-CoV-2 infections was 4.3 times greater (95% confidence interval = 2.2, 7.5) than the number of reported cases. Field surveys with representative sampling provide data that may help fill in gaps in traditional public health reporting. (Am J Public Health. 2022;112(1):38-42. https://doi.org/10.2105/AJPH.2021.306568).